伴放线聚集杆菌阳性牙周炎龈下刮治联合全身抗生素的额外获益:一项回顾性分析
该回顾性分析纳入425例Ⅲ/Ⅳ期B/C级牙周炎患者,比较检出伴放线聚集杆菌后龈下刮治联合全身抗生素(AB组144例)与未联合抗生素(nAB组281例)的效果。T1时AB组37%患者达到治疗目标终点,nAB组27%(p=.038);T2时分别为63%和43%(p=.001)。
要点
- 检出伴放线聚集杆菌后联合全身抗生素,T1达标率37% vs 27%(p=.038)。
- T2时AB组63%达标,nAB组43%(p=.001),联合抗生素组更高。
- AB组144例、nAB组281例,T2随访332例(AB 121/nAB 211)。
核心结论
- 在Ⅲ/Ⅳ期B/C级牙周炎且龈下检出伴放线聚集杆菌的患者中,龈下刮治联合全身抗生素较未联合抗生素获得更高的治疗目标终点达标率。
研究设计与样本
- 回顾性分析,筛选德国法兰克福歌德大学牙周科2008年至2018年间接受微生物检测的患者。
- 纳入425例Ⅲ/Ⅳ期B/C级牙周炎患者(Ⅲ期280例/Ⅳ期145例,B级95例/C级330例),AB组144例、nAB组281例。
- 临床检查于基线(T0)、龈下刮治后12.4(9.4/15.1)周(T1)及末次牙周支持治疗时(T2;T1后3.1[1.4/5.5]年)进行。
主要发现
- T1时AB组53例(37%)达到治疗目标终点,nAB组76例(27%),p=.038。
- T2时AB组76例(63%)达到治疗目标终点,nAB组91例(43%),p=.001。
- T2时提供完整数据者332例(AB组121例/nAB组211例)。
关键数值与推荐
- 治疗目标终点定义为探诊深度≥5 mm的位点≤4个。
- 伴放线聚集杆菌检测阳性者龈下刮治联合全身抗生素(AB组),其余未联合(nAB组)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To evaluate subgingival instrumentation (SI) in periodontitis stage III and IV, grade B and C with systemic antibiotics (AB) only after detection of Aggregatibacter actinomycetemcomitans. MATERIALS AND METHODS: Patients of the Department of Periodontology of Goethe University Frankfurt/Germany were screened for microbiological testing between 2008 and 2018. All patients with aggressive and generalized severe chronic periodontitis were tested. In case of positive subgingival A. actinomycetemcomitans tests, SI was combined with AB; in all other cases it was not (nAB). Clinical examinations were performed before (T0), 12.4 (9.4/15.1) weeks after SI (T1), and at the last supportive periodontal care (T2; 3.1 [1.4/5.5] years after T1). Results at T1/T2 were assessed as "treat-to-target" endpoint (≤4 sites with probing pocket depths ≥5 mm). RESULTS: Four-hundred and twenty-five patients (280 stage III/145 stage IV, 95 grade B/330 grade C) provided complete data (AB 144/nAB 281) for T0 and T1, and 332 (AB 121/nAB 211) for T2. At T1/T2, AB resulted in 53 (37%)/76 (63%) patients with "treat-to-target" endpoint, and nAB in 76 (27%)/91 (43%) (p = .038/.001). CONCLUSIONS: In periodontitis stage III and IV, grade B and C with subgingival A. actinomycetemcomitans infection, SI with AB resulted in higher rate of "treat-to-target" endpoint than exclusive SI in patients without the infection.
引用
- Benz L, Winkler P, Dannewitz B, et al. Additional benefit of systemic antibiotics in subgingival instrumentation of stage III and IV periodontitis with Aggregatibacter actinomycetemcomitans: A retrospective analysis. J Clin Periodontol. 2023. PMID: 36644800. doi:10.1111/jcpe.13777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。